OMER - オメロス (Omeros Corporation) オメロス

 OMERのチャート


 OMERの企業情報

symbol OMER
会社名 Omeros Corp (オメロス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 オメロス(Omeros Corporation)はバイオ医薬品会社である。同社は大規模市場、炎症、凝固障害及び中枢神経系の障害を標的とする孤児の適応症のための小分子及びタンパク質治療薬の発見、開発、商業化に従事する。白内障手術と眼内レンズ(IOL)の交換時に市販されている医薬品Omidria(フェニレフリンとケトロラク注射)が使用される。Omidriaは、眼科的、関節鏡的、泌尿器科学的及び他の外科的処置を受けている患者のために設計されたPharmacoSurgeryプラットフォームに由来する。PharmacoSurgeryプラットフォームは、米国食品医薬品局(FDA)が承認した治療薬の低用量の組み合わせに基づいて、手術中に炎症と先天性外傷による他の問題を抑制するための手術期間中、 手術中及び手術後の両方で臨床的補助を提供する。   オメロスは米国のバイオ医薬品企業。炎症、凝固障害、中枢神経系障害の治療薬の開発、商品化に従事。眼科学向けOMS302、関節鏡処置OMS103HP、泌尿器科向けOMS201、認知障害OMS824、虐待依存症向けPPARg Programなどの臨床プログラムを手掛けるほか、運動障害治療向けOMS527などの前臨床プログラムを手掛ける。   Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under priority review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in a Phase 1 clinical trial, and the company's PDE7 inhibitor program OMS527, targeting addiction and movement disorders, has successfully completed a Phase 1 trial. Omeros' pipeline holds a diverse group of preclinical programs including a proprietary-asset-enabled antibody-generating technology and a proprietary GPCR platform through which it controls 54 GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing GPR174-targeting antibodies and small-molecule inhibitors.
本社所在地 201 Elliott Avenue West Seattle WA 98119 USA
代表者氏名 Gregory A. Demopulos グレゴリーA.デモプス
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 206-676-5000
設立年月日 34486
市場名 NASDAQ National Market System
ipoyear 2009年
従業員数 173人
url www.omeros.com
nasdaq_url https://www.nasdaq.com/symbol/omer
adr_tso
EBITDA EBITDA(百万ドル) -76.79100
終値(lastsale) 14.75
時価総額(marketcap) 716257286
時価総額 時価総額(百万ドル) 770.15870
売上高 売上高(百万ドル) 38.66000
企業価値(EV) 企業価値(EV)(百万ドル) 812.11270
当期純利益 当期純利益(百万ドル) -87.78300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Omeros Corporation revenues decreased 89% to $3.2M. Net loss increased from $29.4M to $63.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 55% to $35.2M (expense) Interest expense increase of 21% to $6.5M (expense).

 OMERのテクニカル分析


 OMERのニュース

   Omeros stock rises 7% after beating Q1 earnings estimate  2022/05/11 16:27:02 Seeking Alpha
Omeros <> stock rose after the company posted better than-expected Q1 earnings, helped by royalties from ophthalmic product Omidria. Net loss for the quarter was $33M or $0.53…
   52 Stocks Moving In Wednesday''s Mid-Day Session  2022/05/11 16:25:49 Benzinga
Gainers Trecora Resources (NYSE: TREC ) shares jumped 26.6% to $9.56 as the company agreed to be acquired by an affiliate of Balmoral Funds at $9.81 per share in cash or an enterprise value of $247 million. Exicure, Inc. (NASDAQ: XCUR ) rose 22.3% to $0.13 after the company reported a $5 million raise in private placement transaction priced at market premium. Purple Innovation, Inc. (NASDAQ: PRPL ) shares jumped 20.7% to $3.7664 after the company reported better-than-expected Q1 EPS and sales results. Endeavour Silver Corp. (NYSE: EXK ) surged 20% to $3.7291 following upbeat quarterly results. Ferroglobe PLC (NASDAQ: GSM ) gained 18.4% to $7.53 after the company reported better-than-expected Q1 EPS results. Celsius Holdings, Inc. (NASDAQ: CELH ) surged 16.4% to $48.10 after the company reported better-than-expected Q1 sales results. H&R Block, Inc. (NYSE: HRB ) gained 16% to $27.55 as the company posted upbeat Q3 results and raised FY22 sales guidance. Callaway Golf Company (NYSE: ELY ) jumped 15.9% to $20.81 after the company reported better-than-expected Q1 EPS and sales results and issued FY22 revenue guidance above analyst estimates.
   Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call Transcript  2022/05/11 02:26:03 Seeking Alpha
Omeros Corporation (NASDAQ:NASDAQ:OMER) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman &…
   Omeros GAAP EPS of -$0.53 beats by $0.08  2022/05/10 20:07:20 Seeking Alpha
Omeros press release (OMER): Q1 GAAP EPS of -$0.53 beats by $0.08.Omeros earned royalties of $13.8M based on Rayner’s net sales of $27.7M, all of which were in the U.S., a $6.6M…
   Omeros Corporation Reports First Quarter 2022 Financial Results  2022/05/10 20:02:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2022, which include: On December
   Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022  2022/05/04 12:30:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2022, on Tuesday, May 10, 2022, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details To access the live conference call via phone, pl
   Omeros Corporation (NASDAQ: OMER): This Is The Year For Success Over The Next Few Months  2022/05/04 12:00:00 Marketing Sentinel
In the last trading session, 1.39 million Omeros Corporation (NASDAQ:OMER) shares changed hands as the company’s beta touched 0.71. With the company’s per share price at $3.30 changed hands at -$0.07 or -2.08% during last session, the market valuation stood at $225.49M. OMER’s last price was a discount, traded about -471.52% off its 52-week high … Omeros Corporation (NASDAQ: OMER): This Is The Year For Success Over The Next Few Months Read More »
   Omeros Stock: The Weight Of The Wait, A Conundrum (NASDAQ:OMER)  2022/05/03 02:18:21 Seeking Alpha
Omeros has fallen on hard times. Click here to read my update on the status of its OMIDRIA sale, financial posture and the conundrum weighing on OMER stock.
   Omeros Corporation (NASDAQ: OMER) Shares Have Been Down About -36.08% Year-To-Date Since The Beginning Of 2022  2022/04/23 14:00:00 Marketing Sentinel
During the last session, Omeros Corporation (NASDAQ:OMER)’s traded shares were 0.6 million, with the beta value of the company hitting 0.56. At the end of the trading day, the stock’s price was $4.11, reflecting an intraday loss of 0.00% or $0.0. The 52-week high for the OMER share is $19.21, that puts it down -367.4 … Omeros Corporation (NASDAQ: OMER) Shares Have Been Down About -36.08% Year-To-Date Since The Beginning Of 2022 Read More »
   Omeros Corporation (NASDAQ:OMER) Currently -237.8% Below Its 52-Week High But The Downside Potential May Surprise You  2022/04/09 17:00:00 Marketing Sentinel
In last trading session, Omeros Corporation (NASDAQ:OMER) saw 0.74 million shares changing hands with its beta currently measuring 0.51. Company’s recent per share price level of $5.74 trading at -$0.18 or -3.04% at ring of the bell on the day assigns it a market valuation of $358.29M. That closing price of OMER’s stock is at … Omeros Corporation (NASDAQ:OMER) Currently -237.8% Below Its 52-Week High But The Downside Potential May Surprise You Read More »
   Omeros Corporation''s (OMER) CEO Greg Demopulos On Q4 2021 Results - Earnings Call Transcript  2022/03/02 01:01:08 Seeking Alpha
   Omeros Non-GAAP EPS of -$0.37 misses by $0.31  2022/03/01 21:04:57 Seeking Alpha
Omeros press release (OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31.At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available…
   Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results  2022/03/01 21:02:00 Business Wire
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include
   Highbridge Capital Management Llc Buys Live Nation Entertainment Inc, Envestnet Inc, Omeros ...  2022/02/18 02:38:03 GuruFocus
Related Stocks: QTNT , RVAC , NSTD , NSTC , CLIM , GSQB , LYV , ENV , OMER , PSTH , CLVS , PCRX , GFLU , KKR , VIAC , HCVIU , ROLL , AQNU , KCGI.U , CFVI , VCXAU ,
   Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next?  2022/02/12 21:00:00 Marketing Sentinel
Omeros Corporation (NASDAQ:OMER)s traded shares stood at 0.34 million during the last session, with the companys beta value hitting 0.63. At the close of trading, the stocks price was $6.32, to imply a decrease of -1.86% or -$0.12 in intraday trading. The OMER shares 52-week high remains $23.85, putting it -277.37% down since that peak Omeros Corporation (NASDAQ: OMER) Has Fallen -277.37% From Its Highs, What Comes Next? Read More »

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オメロス OMER Omeros Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)